Towards Healthcare Research & Consulting

CAR T-Cell Therapy for Solid Tumors Companies, Business & Management Outlook

Date : 08 July 2026

Top Vendors & Their Offerings in the CAR T-Cell Therapy for Solid Tumors Market

CAR T-Cell Therapy for Solid Tumors Market Companies are CARsgen Therapeutics, BioNTech, Autolus Therapeutics, Gilead Sciences (Kite Pharma), Novartis, Legend Biotech, Bristol Myers Squibb (BMS), Atara Biotherapeutics, Noile-Immune Biotech, Immatics

Market Ecosystem Analysis

Ecosystem Category Key Participants Explanation
Technology Providers Cellectis, Lyell Immunopharma, A2 Biotherapeutics, Cartesian Therapeutics Develop advanced CAR engineering, gene editing, armored CARs, logic-gated CAR technologies.
Product Manufacturers Bristol Myers Squibb, Gilead Sciences (Kite), Johnson & Johnson, Autolus Therapeutics Manufacture clinical-stage and commercial CAR T-cell therapies and related cell products.
Service Providers Lonza, Catalent Cell & Gene Therapy, Charles River Laboratories Manufacturing support, analytical testing, process development, logistics.
Platform Providers Celyad Oncology, CARGO Therapeutics, Cellectis, Adaptimmune Therapeutics Proprietary CAR platforms, allogeneic technologies, T-cell engineering platforms.
CROs/CDMOs Lonza, WuXi Advanced Therapies, Charles River Laboratories, Minaris Regenerative Medicine Cell therapy manufacturing, process optimization, clinical manufacturing and testing.
Software Vendors Veeva Systems, Benchling, Dotmatics Clinical data management, laboratory informatics, cell engineering workflow management.
Research Institutions University of Pennsylvania, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, City of Hope, National Cancer Institute Conduct pioneering CAR-T research, translational studies and clinical trials for solid tumors.
End-User Industries Hospitals, Oncology Centers, Academic Research Institutes, Biotechnology Companies, Pharmaceutical Companies Utilize CAR T therapies for research, clinical trials and patient treatment.

What are the Recent Developments in the CAR T-Cell Therapy for Solid Tumors Market?

  • In June 2026, Ever Supreme launched a Phase IIa clinical trial for CAR001 to speed up the global market progression.
  • In April 2026, Roswell Park Comprehensive Cancer Center unveiled an exclusive phase 1 clinical trial of a novel chimeric antigen receptor (CAR) T-cell therapy for patients with acute myeloid leukemia (AML).

Competitive Landscape

Tier 1
Company Name Headquarters Country Why Relevant to This Market Key Products/Services
Bristol Myers Squibb Princeton, New Jersey USA Global CAR-T leader actively developing next-generation solid tumor CAR-T programs following Celgene acquisition. Breyanzi platform, engineered CAR-T pipeline for solid tumors
Gilead Sciences (Kite Pharma) Foster City, California USA Largest commercial CAR-T developer with extensive solid tumor clinical pipeline. Kite CAR-T platform, next-generation solid tumor candidates
Johnson & Johnson New Brunswick, New Jersey USA Invests heavily in cellular immunotherapy through collaborations and internal oncology pipeline. CAR-T research programs targeting solid tumors
AstraZeneca Cambridge United Kingdom Strong investment in cellular therapies through acquisitions and partnerships focused on solid tumors. TCR/CAR-T oncology programs
Novartis AG Basel Switzerland Pioneer in CAR-T with continued expansion into next-generation solid tumor therapies. CAR-T discovery platform, solid tumor pipeline
Tier 2
Company Name Headquarters Country Why Relevant to This Market Key Products/Services
Adaptimmune Therapeutics Abingdon, Oxfordshire United Kingdom Leading engineered T-cell company with active solid tumor cell therapy programs. SPEAR T-cell and CAR-T programs
Cellectis Paris France Pioneer in allogeneic gene-edited CAR-T technology with multiple solid tumor programs. UCART platform, gene-edited CAR-T
Lyell Immunopharma South San Francisco, California USA Focuses on overcoming T-cell exhaustion in solid tumors. Enhanced CAR-T technologies
Celyad Oncology Mont-Saint-Guibert Belgium Specialized CAR-T developer with multiple solid tumor assets. NKR CAR-T platform
Autolus Therapeutics London United Kingdom Advanced engineered CAR-T developer expanding beyond hematologic cancers. Modular CAR-T technologies
Tier 3
Company Name Headquarters Country Why Relevant to This Market Key Products/Services
A2 Biotherapeutics Agoura Hills, California USA Develops logic-gated CAR-T therapies specifically designed for solid tumors. Tmod CAR-T platform
CARGO Therapeutics San Carlos, California USA Developing next-generation CAR-T technologies including solid tumor approaches. Novel CAR-T engineering platform
Cartesian Therapeutics Gaithersburg, Maryland USA Develops RNA-based cell therapies including engineered CAR-T technologies. mRNA CAR-T platform
CARsgen Therapeutics Shanghai China Clinical-stage leader focused heavily on gastrointestinal solid tumors. Claudin18.2 CAR-T therapies
Triumvira Immunologics Hamilton, Ontario Canada Developing TAC-T platform designed to improve efficacy in solid tumors. TAC-T cell therapies

Market Growth

The global CAR T-cell therapy for solid tumors market size is calculated at USD 1.42 billion in 2025, driven by ideal R&D funding, advancements in tumor antigen targeting, & next-generation gene editing platforms. The market continues to grow USD 1.83 billion in 2026 due to technological innovation focused on bypassing the immunosuppressive tumor microenvironment & tackling antigen heterogeneity. It is expected to reach USD 17.98 billion by 2035, expanding at a CAGR of 28.9% as continued ‘armored’ CAR designs, off-the-shelf therapies, & combination treatments.

CAR T-Cell Therapy for Solid Tumors Market Size is USD 2.19 Billion in 2026.